Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium (U54 Clinical Trial Not Allowed)

Funding Opportunity RFA-CA-19-016 from the NIH Guide for Grants and Contracts. The FOA will focus on fusion oncoproteins found in tumors that have high risk of treatment failure and for which there has been little progress in identifying targeted agents. Responsive applications can focus on any fusion oncoprotein in pediatric solid tumors or on NUP98 fusion proteins that occur in young children with acute myelogenous leukemia (AML). However, greater preference will be given to applications focused on PAX-FOXO (alveolar rhabdomyosarcoma), C11orf95RELA (ependymoma), or NUP98 fusion proteins.
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding